首页> 外文期刊>Diabetes care >Impact of insulin resistance on risk of type 2 diabetes and cardiovascular disease in people with metabolic syndrome.
【24h】

Impact of insulin resistance on risk of type 2 diabetes and cardiovascular disease in people with metabolic syndrome.

机译:胰岛素抵抗对代谢综合征患者2型糖尿病和心血管疾病风险的影响。

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

OBJECTIVE: Metabolic syndrome increases the risk for type 2 diabetes and cardiovascular disease (CVD) and may be associated with insulin resistance. RESEARCH DESIGN AND METHODS: We tested the hypothesis that the metabolic syndrome confers risk with or without concomitant insulin resistance among 2,803 Framingham Offspring Study subjects followed up to 11 years for new diabetes (135 cases) or CVD (240 cases). We classified subjects by presence of metabolic syndrome (using the National Cholesterol Education Program's [NCEPs] Third Adult Treatment Panel [ATP III], International Diabetes Federation [IDF], or European Group for the Study of Insulin Resistance [EGIR] criteria) and insulin resistance (homeostasis model assessment of insulin resistance > or = 75th percentile) and used separate risk factor-adjusted proportional hazards models to estimate relative risks (RRs) for diabetes or CVD using as referents those without insulin resistance, metabolic syndrome, or without both. RESULTS: Fifty-six percent of individuals with ATP III, 52% with IDF, and 100% with EGIR definitions of metabolic syndrome had insulin resistance. Insulin resistance increased risk for diabetes (RR 2.6 [95% CI 1.7-4.0]) and CVD (1.8 [1.4-2.3]) as did metabolic syndrome for diabetes (ATP III, 3.5 [2.2-5.6]; IDF, 4.6 [2.7-7.7]; and EGIR, 3.3 [2.1-5.1]) and CVD (ATP III, 1.8 [1.4-2.3]; IDF, 1.7 [1.3-2.3]; and EGIR, 2.1 [1.6-2.7]). Relative to those without either metabolic syndrome or insulin resistance, metabolic syndrome and insulin resistance increased risk for diabetes (ATP III, 6.0 [3.3-10.8] and IDF, 6.9 [3.7-13.0]) and CVD (ATP III, 2.3 [1.7-3.1] and IDF, 2.2 [1.6-3.0]). Any instance of metabolic syndrome without insulin resistance increased risk for diabetes approximately threefold (P < 0.001); IDF metabolic syndrome without insulin resistance (RR 1.6, P = 0.01), but not ATP III metabolic syndrome without insulin resistance (RR 1.3, P = 0.2), increased risk for CVD. CONCLUSIONS: Metabolic syndrome increased risk for diabetes regardless of insulin resistance. Metabolic syndrome by ATP III criteria may require insulin resistance to increase risk for CVD. The simultaneous presence of metabolic syndrome and insulin resistance identifies an especially high-risk individual.
机译:目的:代谢综合征会增加2型糖尿病和心血管疾病(CVD)的风险,并可能与胰岛素抵抗相关。研究设计和方法:我们测试了2803名Framingham后代研究对象中,新陈代谢综合征可伴有或不伴有胰岛素抵抗风险的假设,随访11年的新糖尿病(135例)或CVD(240例)。我们根据代谢综合征的存在对受试者进行分类(使用国家胆固醇教育计划的[NCEPs]第三成人治疗小组[ATP III],国际糖尿病联合会[IDF]或欧洲胰岛素抵抗研究[EGIR]标准小组)抵抗力(胰岛素抵抗的稳态模型评估>或=第75个百分位数),并使用单独的危险因素调整比例风险模型来评估糖尿病或CVD的相对风险(RRs),并以没有胰岛素抵抗,代谢综合症或两者都不存在的人为参考。结果:56%的ATP III患者,52%的IDF患者和100%的EGIR代谢综合征患者具有胰岛素抵抗。胰岛素抵抗增加了糖尿病的代谢风险(ATP III,3.5 [2.2-5.6]; IDF,4.6 [2.7],患糖尿病的风险(RR 2.6 [95%CI 1.7-4.0])和CVD(1.8 [1.4-2.3]) -7.7]; EGIR,3.3 [2.1-5.1])和CVD(ATP III,1.8 [1.4-2.3]; IDF,1.7 [1.3-2.3]; EGIR,2.1 [1.6-2.7])。相对于那些既没有代谢综合征也没有胰岛素抵抗的人,代谢综合征和胰岛素抵抗增加了患糖尿病(ATP III,6.0 [3.3-10.8]和IDF,6.9 [3.7-13.0])和CVD(ATP III,2.3 [1.7- 3.1]和IDF,2.2 [1.6-3.0])。没有胰岛素抵抗的代谢综合征的任何病例都会使糖尿病的风险增加大约三倍(P <0.001);没有胰岛素抵抗的IDF代谢综合征(RR 1.6,P = 0.01),但没有胰岛素抵抗的ATP III代谢综合征(RR 1.3,P = 0.2),则增加了CVD的风险。结论:无论胰岛素抵抗如何,代谢综合征都会增加患糖尿病的风险。根据ATP III标准进行的代谢综合征可能需要胰岛素抵抗才能增加CVD的风险。代谢综合症和胰岛素抵抗的同时存在,确定了一个特别高风险的个体。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号